Drugs / FH-006
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07136142 | Aug 2025 → Feb 2027 expected | cancer | Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06735144 | Dec 2024 → Dec 2027 expected | cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07241767 | Nov 2025 → Nov 2027 expected | lung cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FH-006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07136142 ↗ |
| Route | Intravenous | “Intravenous injection” NCT06735144 ↗ |